Patents by Inventor Yves Rival

Yves Rival has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11224566
    Abstract: A composition comprising, in a physiologically acceptable medium, a crosslinked hyaluronic acid (HA), having a degree of modification less than 1.9 mole %; a HA with a molecular weight of about 50 kDa or less; and/or an agent stimulating endogenous HA synthesis. Also disclosed is a cosmetic use of such composition in skin care and/or anti-ageing treatment.
    Type: Grant
    Filed: June 26, 2019
    Date of Patent: January 18, 2022
    Assignee: Galderma Holding SA
    Inventors: Claire Mallard, Yves Rival
  • Patent number: 10959934
    Abstract: A micro- or nanoparticular vesicle comprises at least a crosslinked hyaluronic acid (HA), wherein the crosslinked hyaluronic acid is crosslinked by a chemical crosslinking agent, and wherein the degree of modification of said crosslinked hyaluronic acid with said chemical crosslinking agent is less than 1.9 mole %. Also disclosed are a method of manufacturing such vesicles, compositions comprising such vesicles and their uses.
    Type: Grant
    Filed: June 26, 2019
    Date of Patent: March 30, 2021
    Assignee: GALDERMA HOLDING SA
    Inventors: Claire Mallard, Yves Rival
  • Publication number: 20190314263
    Abstract: A composition comprising, in a physiologically acceptable medium, a crosslinked hyaluronic acid (HA), having a degree of modification less than 1.9 mole %; a HA with a molecular weight of about 50 kDa or less; and/or an agent stimulating endogenous HA synthesis. Also disclosed is a cosmetic use of such composition in skin care and/or anti-ageing treatment.
    Type: Application
    Filed: June 26, 2019
    Publication date: October 17, 2019
    Inventors: Claire MALLARD, Yves RIVAL
  • Publication number: 20190314649
    Abstract: A micro- or nanoparticular multilamellar vesicle is constituted of concentric membranes comprising at least one non-ionic surfactant of the sucrose ester type comprising at least one chain arising from a linear or branched, saturated or unsaturated, optionally mono- or polyhydroxylated C12 to C22 fatty acid, which vesicle comprises at least a hyaluronic acid (HA), wherein the hyaluronic acid is a crosslinked hyaluronic acid. Also disclosed are a method of manufacture of such vesicle, compositions comprising such vesicle and their uses.
    Type: Application
    Filed: June 26, 2019
    Publication date: October 17, 2019
    Inventors: Claire MALLARD, Yves RIVAL, Lise ANTHONIOZ
  • Publication number: 20190314262
    Abstract: A micro- or nanoparticular vesicle comprises at least a crosslinked hyaluronic acid (HA), wherein the crosslinked hyaluronic acid is crosslinked by a chemical crosslinking agent, and wherein the degree of modification of said crosslinked hyaluronic acid with said chemical crosslinking agent is less than 1.9 mole %. Also disclosed are a method of manufacturing such vesicles, compositions comprising such vesicles and their uses.
    Type: Application
    Filed: June 26, 2019
    Publication date: October 17, 2019
    Inventors: Claire MALLARD, Yves RIVAL
  • Patent number: 9187438
    Abstract: The object of the present invention is benzothiazine derivatives having the capability of inhibiting 11?-HSD1 not only at an enzymatic level but also at a cell level. The compounds of the present invention are of general formula (I). Wherein notably R1 represents a hydrogen or OR1 represents an ester or an ether. R2 represents a naphthyl or a 1,2,3,4-tetrahydro-naphthalene or a biphenyl or phenyl pyridine or a substituted phenyl. R3 represents a methyl or ethyl; R4 and R?4 represent a hydrogen.
    Type: Grant
    Filed: March 2, 2010
    Date of Patent: November 17, 2015
    Assignee: PIERRE FABRE MEDICAMENT
    Inventors: Michel Perez, Marie Lamothe, Didier Junquero, Yves Rival
  • Patent number: 8618287
    Abstract: The present invention relates to derivatives of general formula I wherein: —W represents nitrogen, —R1 represents: •a hydrogen or a linear or branched C1-C5 alkyl radical or, •a C1-C3 alkyl radical substituted with groups such as trifluoromethyl, nitrile, hydroxy, C1-C3 alcoxy, C3-C6 alkoxyalkoxy, indolyl, thiophenyl, oxothiophenyl, C1-C3 N-alkylcarbamoyl groups or, •a phenyl or pyridyl or naphthyl, or thiophenyl group optionally substituted with one or more groups such as halogen atoms, nitro, nitrile, trifluoromethyl, vinyl, methylsulfanyl, linear branched C1-C4 alkyl, linear or branched C1-C3 alkoxy groups, •a C6 2-oxocycloalkyl radical—R2 represents a methyl or heptyl, -m, n are equal to 1, —V represents CH2, —X—Y represents —N— (C?O)—, —CH—O—, —Z represents a phenyl group substituted with one or more trifluoromethyl groups, halogen atoms or linear C1-C4 alkyl groups.
    Type: Grant
    Filed: July 7, 2009
    Date of Patent: December 31, 2013
    Assignee: Pierre Fabre Medicament
    Inventors: Isabelle Leroy, Elisabeth Dupont-Passelaigue, Karine Valeille, Yves Rival, Didier Junquero
  • Publication number: 20110319326
    Abstract: The object of the present invention is benzothiazine derivatives having the capability of inhibiting 11?-HSD1 not only at an enzymatic level but also at a cell level. The compounds of the present invention are of general formula (I). Wherein notably R1 represents a hydrogen or OR1 represents an ester or an ether. R2 represents a naphthyl or a 1, 2, 3, 4-tetrahydro-naphthalene or a biphenyl or phenyl pyridine or a substituted phenyl. R3 represents a methyl or ethyl; R4 and R?4 represent a hydrogen.
    Type: Application
    Filed: March 2, 2010
    Publication date: December 29, 2011
    Applicant: PIERRE FABRE MEDICAMENT
    Inventors: Michel Perez, Marie Lamothe, Didier Junquero, Yves Rival
  • Publication number: 20110118266
    Abstract: The present invention relates to derivatives of general formula I wherein: —W represents nitrogen, —R1 represents: •a hydrogen or a linear or branched C1-C5 alkyl radical or, •a C1-C3 alkyl radical substituted with groups such as trifluoromethyl, nitrile, hydroxy, C1-C3 alcoxy, C3-C6 alkoxyalkoxy, indolyl, thiophenyl, oxothiophenyl, C1-C3 N-alkylcarbamoyl groups or, •a phenyl or pyridyl or naphthyl, or thiophenyl group optionally substituted with one or more groups such as halogen atoms, nitro, nitrile, trifluoromethyl, vinyl, methylsulfanyl, linear branched C1-C4 alkyl, linear or branched C1-C3 alkoxy groups, •a C6 2-oxocycloalkyl radical—R2 represents a methyl or heptyl, —m, n are equal to 1, —V represents CH2, —X—Y represents —N— (C?O)—, —CH—O—, —Z represents a phenyl group substituted with one or more trifluoromethyl groups, halogen atoms or linear C1-C4 alkyl groups.
    Type: Application
    Filed: July 7, 2009
    Publication date: May 19, 2011
    Applicant: PIERRE FABRE MEDICAMENT
    Inventors: Isabelle Leroy, Elisabeth Dupont-Passelaigue, Karine Valeille, Yves Rival, Didier Junquero
  • Patent number: 7713971
    Abstract: The invention relates to 3,5-dioxo-(2H,4H)-1,2,4-triazine compounds of formula I in which the variables are defined herein, as well as additive salts with pharmaceutically acceptable bases and the various enantiomers of compounds having asymmetrical carbons, as well as their mixtures in all proportions, including racemic mixtures in particular.
    Type: Grant
    Filed: March 2, 2006
    Date of Patent: May 11, 2010
    Assignee: Pierre Fabre Medicament
    Inventors: Elisabeth Dupont-Passelaigue, Isabelle Leroy, Jean-François Patoiseau, Didier Junquero, Yves Rival, André Delhon
  • Publication number: 20080167313
    Abstract: The invention concerns 3,5-dioxo-(2H,4H)-1,2,4-triazine derivatives of general formula (I), wherein: R1 and R2, identical or different, represent a branched or linear C1-C7 alkyl or alkenyl radical, a C1-C6 alkyl radical substituted by groups such as trifluoromethyl, C5-C6 cycloalkyl, nitrile, C1-C4 alkoxycarbonylvinyl, hydroxycarbonylvinyl, C1-C4 alkoxycarbonyl, carboxylate, benzyloxy or phenyl (for which the phenyl ring is optionally substituted by one or more groups such as C1-C4 alkoyl, C1-C4 alkoxy, nitro, halogen, trifluoromethyl); YR3 represents oxygen or NR3 for which R3 represents hydrogen, a linear or branched C1-C7 alkyl or alkenyl radical, a C1-C6 alkyl radical substituted by groups such as trifluoromethyl or phenyl (for which the phenyl ring is optionally substituted by one or more groups such as C1-C4 alkoyl, C1-C4 alkoxy, nitro, halogen, trifluoromethyl); Z represents an oxygen atom or a carbon atom capable of being bound to the ortho, meta or para positions of the phenyl group of formula I; n
    Type: Application
    Filed: March 2, 2006
    Publication date: July 10, 2008
    Applicant: Pierre Fabre Medicament
    Inventors: Elisabeth Dupont-Passelaigue, Isabelle Leroy, Jean-Francois Patoiseau, Didier Junquero, Yves Rival, Andre Delhon